What is HC Wainwright’s Forecast for GPCR FY2024 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR) – HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Structure Therapeutics in a research note issued to investors on Wednesday, December 4th. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings per share of ($0.77) for the year. HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.73) EPS and FY2028 earnings at ($1.81) EPS.

Other equities analysts also recently issued reports about the stock. JMP Securities reduced their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, Morgan Stanley began coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $85.67.

Structure Therapeutics Price Performance

GPCR opened at $33.35 on Friday. The company has a market capitalization of $1.91 billion, a P/E ratio of -45.07 and a beta of -3.41. The firm’s fifty day moving average price is $37.29 and its two-hundred day moving average price is $39.30. Structure Therapeutics has a fifty-two week low of $26.61 and a fifty-two week high of $62.85.

Institutional Trading of Structure Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. acquired a new position in shares of Structure Therapeutics in the 2nd quarter worth approximately $6,489,000. Natixis Advisors LLC grew its holdings in shares of Structure Therapeutics by 29.4% during the second quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock worth $746,000 after purchasing an additional 4,321 shares during the last quarter. Gilbert & Cook Inc. bought a new stake in shares of Structure Therapeutics during the second quarter worth $229,000. TD Asset Management Inc increased its stake in shares of Structure Therapeutics by 47.9% in the second quarter. TD Asset Management Inc now owns 211,590 shares of the company’s stock valued at $8,309,000 after buying an additional 68,490 shares in the last quarter. Finally, Pier Capital LLC raised its holdings in shares of Structure Therapeutics by 3.7% in the second quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock valued at $3,974,000 after buying an additional 3,647 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.